Study of DNA Samples From Patients With Multiple Myeloma
NCT ID: NCT00898040
Last Updated: 2017-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
600 participants
OBSERVATIONAL
2006-07-06
2007-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is looking at DNA samples from patients with multiple myeloma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia
NCT00897936
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
NCT00898066
S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia
NCT01434329
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
NCT04955808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine whether there is an increased frequency of 1 or more polymorphic alleles that are associated with clinical endpoints using custom myeloma single nucleotide polymorphism (SNP) chip analysis of banked DNA samples from patients with multiple myeloma.
* Determine SNPs associated with toxicities caused, not by variations in tumor cell genetics, but by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME).
* Determine SNPs associated with response, influenced by the same ADME.
* Determine SNPs associated with bone disease (as a variable) among patients with multiple myeloma.
* Determine SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma).
OUTLINE: This is a retrospective, multicenter study.
Banked DNA samples are analyzed using a custom single nucleotide polymorphism (SNP) chip to assess approximately 3,590 SNPs from 1,061 genes that are associated with myeloma growth and response.
PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
polymorphism analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of multiple myeloma
* DNA samples banked from other ECOG studies (and other clinical trial groups \[e.g., SWOG and MRC\])
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
ECOG-ACRIN Cancer Research Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Van Ness
Role: STUDY_CHAIR
Masonic Cancer Center, University of Minnesota
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECOG-E3L06T1
Identifier Type: -
Identifier Source: secondary_id
CDR0000495284
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.